| 陈宇,周振昭,许运承,等.非布司他治疗老年糖尿病肾病合并高尿酸血症疗效及对尿酸的影响[J].安徽医药,2021,25(6):1256-1259. |
| 非布司他治疗老年糖尿病肾病合并高尿酸血症疗效及对尿酸的影响 |
| Clinical effect of febuxostat on senile diabetic nephropathy complicated with hyperuricemia and its effect on uric acid |
| |
| DOI：10.3969/j.issn.1009-6469.2021.06.048 |
| 中文关键词: 糖尿病肾病 高尿酸血症 非布司他 别嘌呤醇 老年人 |
| 英文关键词: Diabetic nephropathies Hyperuricemia Febuxostat Allopurinol Aged |
| 基金项目:深圳市宝安区科技计划基础研究项目( 2019JD379) |
|
| 摘要点击次数: 1983 |
| 全文下载次数: 580 |
| 中文摘要: |
| 目的探讨非布司他治疗老年糖尿病肾病( DN)合并高尿酸血症疗效和安全性。方法将深圳市宝安区妇幼保健院 2017年 1月至 2018年 10月收治的 96例老年 DN合并高尿酸血症病人按照数字随机表法分为两组。每组 48例。两组均给予糖尿病常规治疗。研究组同时给予非布司他片口服， 40毫克 /次， 1次/天，连续服用 12周。对照组在糖尿病常规治疗基础上给予别嘌呤醇片口服， 0.05克/次， 2次/天， 2周后改为 0.1克/次， 3次/天，连续服用 12周。比较两组治疗前后血尿酸、尿白蛋白排泄率( UAER)，尿白蛋白肌酐比( ACR)。比较两组空腹血糖( FBG)、空腹胰岛素( FINS)计算胰岛素抵抗指数( HOMA-IR)，并比较两组治疗总有效率和不良反应发生率。结果治疗后研究组尿酸［(416.23±38.8，9)μmol/L比( 438.55±42.61)μmol/L］、 UAER、ACR、FBG、FINS、HOMA-IR均低于对照组( P<0.05，P<0.01)，治疗总有效率高于对照组( 89.58%比 72.92%，P<0.05)不良反应发生率低于对照组( P<0.05)。结论非布司他可有效降低血尿酸水平，减少微量白蛋白的排泄，治疗老年 DN合并高尿，酸血症疗效确切，不良反应少。 |
| 英文摘要: |
| Objective To explore the efficacy and safety of febuxostatin the treatment of senile diabetic nephropathy (DN) complicated with hyperuricemia.Methods Ninety-six patients with senile DN and hyperuricemia admitted to Bao′an Maternal and ChildHealthcare Hospital from January 2017 to October 2018 were assigned into 2 groups using a digital random number table, with 48 cases in each group. Both groups were given the routine treatment for diabetes. The research group was also given febuxostat orally,40mgeach time, once a day,continuously for 12 weeks. The control group was given allopurinol oral tablets on the basis of conventional treatment, 0.05 g each time, bid. and after 2 weeks, changing to 0.1 g each time,tid,continuously for 12 weeks. Serum uric acid (SUA), urinary albumin excretion rate (UAER), urinary albumin creatinine ratio (ACR) were compared between the two groups before and aftertreatment. The fasting blood glucose (FBG) and fasting insulin (FINS) were compared between the two groups. Insulin resistance index(HOMA-IR) was measured and the total effective rate and incidence of adverse reactions were compared between the two groups.Re? sults The levels of SUA [(416.23±38.89)μmol/L vs. (438.55±42.61)μmol/L], UAER, ACR、 FBG, FINS, HOMA-IR of the research group were lower than those of the control group (P<0.05, P<0.01). The total effective rate of the research group was higher than that of the control group (89.58% vs. 72.92%, P<0.05). The incidence of adverse reactions was lower than that of the control group (P<0.05). Conclusions Febuxostat can effectively reduce the level of SUA and the excretion of microalbumin. So it has effective clinical effectand fewer adverse reactions in the treatment of senile DN complicated with hyperuricemia. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
